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Abstract
Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) are the standard clinical therapy
of diabetic nephropathy (DN), while aldosterone antagonists are only used as adjuncts. Previously in experimental DN we
showed that Na/K ATPase (NKA) is mislocated and angiotensin II leads to superimposed renal progression. Here we
investigated the monotherapeutic effect of aldosterone blockers on the progression of DN and renal NKA alteration in
comparison to ACEi and ARBs. Streptozotocin-diabetic rats developing DN were treated with aldosterone antagonists; ACEi
and ARB. Renal function, morphology, protein level and tubular localization of NKA were analyzed. To evaluate the effect of
high glucose per se; HK-2 proximal tubular cells were cultured in normal or high concentration of glucose and treated with
the same agents. Aldosterone antagonists were the most effective in ameliorating functional and structural kidney damage
and they normalized diabetes induced bradycardia and weight loss. Aldosterone blockers also prevented hyperglycemia
and diabetes induced increase in NKA protein level and enzyme mislocation. A monotherapy with aldosterone antagonists
might be as, or more effective than ACEi or ARBs in the prevention of STZ-induced DN. Furthermore the alteration of the
NKA could represent a novel pathophysiological feature of DN and might serve as an additional target of aldosterone
blockers.
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Introduction
Diabetes mellitus is a complex metabolic disorder with nearly
170 million cases worldwide. The incidence is rapidly increasing
and by the year of 2030 this number will almost double [1].
Diabetic nephropathy (DN) is the predominant cause of chronic
kidney disease (CKD) and accounts for half of the end-stage kidney
disease population [2]. Patients with DN also have abnormal
lipoprotein metabolism and frequently develop severe atheroscle-
rotic and cardiovascular complications resulting in a higher
morbidity and mortality [3]. Since diabetes is a major drain on
health and productivity-related resources for healthcare systems,
the prevention and early treatment of DN would have enormous
social and economical impact. Current therapeutic approaches
based on the guidelines of the European and American Diabetes
Associations still focus on angiotensin converting enzyme inhib-
itors (ACEi) and angiotensin II receptor blockers (ARB) [4,5],
while aldosterone antagonists are only used as adjuncts.
In diabetes the renin-angiotensin-aldosterone system (RAAS) is
clearly activated [6–8], with increased renal angiotensin II
(ANGII) and aldosterone activity. Renal angiotensinogen, angio-
tensin I and ANGII levels are approximately 1,000-fold greater as
compared to their plasma levels [9–11]. Proximal tubules express
angiotensinogen, renin, ACE, and ANGII receptors and facilitate
even local aldosterone production [12] emphasizing the pivotal
role of these cells in renal RAAS.
However glomerular, tubular and interstitial injuries are all
characteristic for DN, alterations of renal RAAS significantly affect
the tubules [13,14]. Na/K ATPase (NKA) is the major force of
sodium transport in proximal tubular cells, and as an ion
transporter it is only active when inserted in its physiological
place in the basal membrane [15]. In the kidney ANGII blocks this
translocation of NKA leading to dysfunctional enzyme activity
[16]. Recently we demonstrated also in streptozotocin (STZ)-
diabetic rats that the renal NKA is mislocated from the tubular
basal membrane toward the cytoplasm and thus becomes non-
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functional. Exogenous ANGII administration led to further
impairment of NKA and superimposed progression of DN
[17,18].
Our aim in the present study was to characterize the
monotherapeutic effect of different aldosterone antagonists in
comparison to other RAAS inhibitors in the pathophysiology of
DN and to investigate the role of NKA. Since both hyperglycemia
and hyperosmolarity are pathological features of diabetes in vivo,
we also investigated the direct effects of hyperglycemia on tubular
cells in vitro.
Results
Aldosterone antagonists ameliorated all metabolic and
renal parameters in STZ-induced diabetic rats
Metabolic and renal parameters are summarized in Table 1.
After 7 weeks of diabetes rats had developed lower body weight
and higher blood glucose level than controls. Serum total
cholesterol, LDL-cholesterol and triglyceride levels were higher
in diabetic rats as compared to controls. Kidney weight to body
weight ratio, serum creatinine, BUN, potassium and protein to
creatinine ratio values were increased, while serum sodium level
was lower in diabetic rats suggesting the presence of renal
hypertrophy and impaired kidney function.
Only Spironolactone prevented weight loss of diabetic animals,
while blood glucose level was lower in all RAAS blocker treated
animals but not normalized. Aldosterone antagonists ameliorated
each lipid profile parameter, while Enalapril and Losartan had no
effect. Parameters representing kidney function were affected as
shown in Table 1: Spironolactone ameliorated all parameters
investigated and Eplerenone was also very effective but failed to
preserve serum creatinine.
Aldosterone blockers attenuated the structural lesions of
DN
The evaluation of DN was based on glomerular lesions
(increased PAS positive area: mesangial matrix expansion and
basal membrane thickening) with a separate assessment of
arteriolar hyalinosis and tubular atrophy (Armanni-Ebstein lesion).
Control kidneys showed normal glomerular structure, no tubular
lesions and minimal arteriolar hyalinosis (Fig. 1/A). Kidneys of
STZ-induced diabetic rats developed severe mesangial matrix
expansion and obliteration of capillaries with regional adhesion of
the glomerular tuft to Bowman’s capsule at the site of mesangial
matrix expansion (Fig. 1/B). These alterations were accompanied
by arteriolar hyalinosis exceeding the mean area of capillary
lumen. The tubules were dilated and lined with flattened
epithelium. Armanni-Ebstein lesions were observed in several
tubules with typical deposits of glycogen.
Mesangial fractional volume value was the lowest in D+Spiro-
nolactone but it was also decreased in the other treatment groups
(Fig. 1/C). Aldosterone antagonists were also effective in
minimizing arteriolar hyalinosis and the presence of Armanni-
Ebstein anomalies (Fig. 1/D–H).
Diabetes and hyperglycemia elevated tubular NKA
protein level
NKA protein level was almost doubled both in kidney
homogenates of STZ-diabetic rats (Fig. 2/A) and hyperglycemic
(35 mM) tubular cells (Fig. 2/B) compared to controls, while
aldosterone antagonists were the most effective in decreasing this
elevated level of NKA (Fig. 2/A–B).
A similar change in osmolarity obtained by the use of 30 mM
mannitol+5 mM glucose failed to reproduce these effects in
tubular cells (data not shown).
Aldosterone inhibitors prevented the mislocation of NKA
induced by diabetes in proximal tubules
NKA distribution showed a linear, basolateral membrane
associated pattern in control animals which was changed to a
cytoplasmic or even to an apical membrane associated staining in
diabetic animals (Fig. 3/A–B). Aldosterone antagonists prevented
this mislocation the most, although the linear staining pattern of
NKA was slightly widened (Fig. 3/C–F).
Aldosterone antagonists restored heart rate in STZ-
induced diabetic rats, while neither diabetes, nor RAAS
blockers influenced MAP
Arterial blood pressure and heart rate were monitored by the
non-invasive tail cuff method. Heart rate was lower in diabetic
animals, but was restored to the level of controls by aldosterone
antagonists (Table 2). MAP remained unchanged after 7 weeks of
untreated diabetes and after the treatment with each RAAS
Table 1. Metabolic and renal parameters of control, diabetic and treated diabetic rats.
Parameter Control Diabetic (D) D+Enalapril D+Losartan D+Spironolactone D+Eplerenone
Body Weight (g) 342613 260629*** 256642 250665 349629111 273655
Blood Glucose (mmol/L) 11.661.1 43.663.2*** 35.665.211 36.165.911 33.262.4111 38.56411
Se-Cholesterol (mmol/L) 1.7260.43 4.162.3* 3.1361.64 2.7260.91 1.6460.3211 2.2860.441
Se-LDL-Cholesterol (mmol/L) UD 1.6361.95* 0.6561 0.4860.54 UD1 UD1
Se-Triglyceride (mmol/L) 1.3260.17 4.9463.7* 4.5465.17 2.4561.51 0.7960.2911 2.1661.171
Kidney/body weight x 100 0.4260.02 0.6760.06*** 0.5360.111 0.5460.0711 0.5660.0711 0.5860.0511
Se-Creatinine (mmol/L) 55.665.4 64.666.7* 57.869.8 54.867.111 56.764.511 67.265.8
Blood Urea Nitrogen (mmol/L) 7.1260.28 1562.8** 11.962.4 11.961.5 8.6161.0511 11.462.31
Se-Potassium (mmol/L) 5.7860.43 7.2660.86** 7.2461.08 660.51 5.3461.3911 6.1260.841
Se-Sodium (mmol/L) 15468.46 13563.7*** 137.263.1 13861 1416211 14062.311
Urinary protein/creatinine 0.1260.02 1.7760.89** 0.1460.03111 0.2160.1111 0.3560.111 0.0460.0211
Data are means 6 SD, n = 8–10/group, *p,0.05 vs. C; 1p,0.05 vs. D, **p,0.01 vs. C; 11p,0.01 vs. D, ***p,0.001 vs. C; 111p,0.001 vs. D; respectively. UD–undetectable.
doi:10.1371/journal.pone.0039938.t001
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inhibitor (Table 2), reflecting the non-depressor dose of the
substances.
Discussion
Since chronic kidney disease due to DN is becoming an ever
larger health burden worldwide more effective therapies are
desperately needed. In the past years ACEi and ARB have become
Figure 1. Renal histopathology in control, diabetic and treated diabetic rats. Aldosterone antagonists were the most effective in
attenuating the structural lesions of DN. Representative PAS staining of kidney sections (40x magnification; scale bar –50 mm): non-diabetic control
(A), STZ-induced diabetic (B), Enalapril (E), Losartan (F), Spironolactone (G) and Eplerenone (H) treated diabetic rats (n = 8–10/group). Long, wide
headed arrows point on mesangial matrix; long, narrow headed arrows on arterioles. Armanni-Ebstein lesions are marked with short, wide headed
arrows. C: Mesangial fractional volume values (Vv) are defined by the ratio of mesangial area/glomerular tuft area. The mesangial area is determined
by assessment of PAS-positive and nucleus-free areas in the mesangium. *p,0.05 vs Control; 1p,0.05 vs Diabetes, respectively; (bars show means 6
SD). D: Arteriolar hyalinosis is defined by the average of hyalinized quarters of arterioles. The hyalin is determined by assessment of PAS-positive and
nucleus-free areas within the arterioles. *p,0.05 vs Control; 1p,0.05 vs Diabetes, respectively; (bars show means 6 SD).
doi:10.1371/journal.pone.0039938.g001
Figure 2. Western blot analysis of Na/K ATPase (NKA). Aldosterone antagonists were the most effective in decreasing diabetes and
hyperglycemia induced elevation of tubular NKA protein level. Top panel: Representative examples of Western blot analysis. Lower panels: A:
Densitometric analysis of NKA protein levels in kidney homogenates of control, diabetic and treated diabetic rats. B: Densitometric analysis of NKA
protein levels in HK-2 tubular cells. Bar graph represents densitometric analysis from multiple experiments. Data represent means 6 SD; *p,0.05 vs
Control; 1p,0.05 vs Diabetes, respectively; (bars show means6SD; n = 8–10/group). IOD – integrated optical density.
doi:10.1371/journal.pone.0039938.g002
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the standard care for diabetic patients with microalbuminuria [5],
however increasing evidence suggests that these agents do not slow
the progression of DN significantly [19,20]. In DN aldosterone
antagonists are still underused since Spironolactone is applied
occasionally as an adjunctive therapy while Eplerenone is not
licensed yet.
Therefore the primary goal of our study was to evaluate the
monotherapeutic efficacy of different aldosterone antagonists in
comparison to ACEi and ARB in the protection against DN.
According to our results aldosterone antagonism both by
Spironolactone or Eplerenone might be a valuable choice to slow
the progression of DN.
Hyperkalemia poses a therapeutic dilemma for the treatment
with aldosterone antagonists, especially in diabetic patients.
However in the recent years several randomized-well controlled
trials showed that in case of monotherapy the incidence of
significant hyperkalemia is relatively low [21,22]. Although we
neither found elevated potassium levels in the aldosterone-
antagonists treated group, according to the literature special
precaution is needed in combination therapy of aldosterone
antagonist with other RAAS blockers, especially in diabetic
patients since diabetes is an independent risk factor for hyperka-
lemia [23].
It has been already suggested that antihypertensive treatment by
different RAAS blockers provide renoprotection independent of
blood pressure lowering. Izuhara et al showed that beyond
decreasing blood pressure the unique renoprotective properties
of ARB olmesartan are also related to other factors (e.g. decreased
oxidative stress, etc) [24]. To test whether this renoprotection of
RAAS blockade is limited to antihypertensive doses, or is also seen
with lower dosages we chose treatment protocols avoiding blood
pressure changes but remaining effective in blocking ACE [25],
ANGII receptor 1 [26] or aldosterone [27].
In the present study neither diabetes nor RAAS blockers
changed blood pressure, which confirms the non-depressor dose of
our protocols. However tachycardia is a well-known feature of
diabetic patients [28]; diabetic rats have proven resting bradycar-
dia [29,30], due to the dysfunction of both the sympathetic and
parasympathetic innervation of the baroreflex [30]. Here only
aldosterone antagonists restored lower heart rates of diabetic
animals back to the level of controls. This effect of Spironolactone
and Eplerenone could be partly explained by the prevention of
baroreceptor and baroreflex depression via inhibiting the aldoste-
rone induced increase of NKA synthesis and activity in the carotid
sinus [31].
In line with previous data [17,32] in the present study untreated
diabetic rats had nearly 25 % lower body weight than controls and
this was prevented by Spironolactone, but not by Eplerenone,
ACEi or ARB. Previously it has been shown that after STZ
treatment body weight of male rats is reduced compared to control
males; but this has been not observed among females [33]. Since
Spironolactone has lower stronger anti-androgenic property (due
to the lack of the 9,11-epoxide group) than Eplerenone [32]; we
hypothesize that Spironolactione might be more effective on the
account of this phenomenon.
In the present study aldosterone inhibitors reduced the elevated
blood glucose level of diabetic animals. Although STZ injection
leads to the destruction of pancreatic ß-cells, a residual insulin
activity still exists even after 6 weeks [34]. Since aldosterone
impairs insulin signaling, it is conceivable that Spironolactone and
Eplerenone might be effective through inhibiting aldosterone
induced insulin resistance [32].
In diabetic patients altered lipoprotein metabolism [3] and an
abnormal lipid profile [35] contribute to accelerated atheroscle-
rosis and increased risk of cardiovascular disease [36]. Parallel to
other animal studies [37], we also detected remarkably elevated
total and LDL-cholesterol and triglyceride levels in diabetic rats.
Aldosterone antagonists improved all lipid parameters, while ACEi
and ARB had no effect. Spironolactone has been already shown to
ameliorate serum lipid parameters [32], but we are the first to
report that Eplerenone is equally effective. Aldosterone antagonists
might exert their beneficial effect partly by decreasing insulin
resistance in the liver [38]. However, it is also conceivable that the
lipid lowering affinity of aldosterone antagonists in diabetes is
provided by inhibiting proinflammatory cytokine production from
white adipose tissue as well [39].
In our study the impaired renal function and increased kidney
to body weight ratio of diabetic animals hints at the toxic effect of
glucose and suggests renal damage. Histological hallmarks of DN
including mesangial matrix expansion, arteriolar hyalinosis and
Armanni-Ebstein lesions were also present in diabetic rats.
Armanni-Ebstein lesions – the vacuolarization of tubular epithelia
– are caused by aggregated glycogen as a result of increased
tubular glucose uptake. The ability of the proximal tubuli to
Figure 3. Confocal images of control, diabetic and treated diabetic rats. Aldosterone inhibitors prevented the mislocation of NKA induced
by diabetes in proximal tubules. Representative pictures of immunofluorescence staining of kidney sections for Na/K ATPase (NKA, green) in control
(A), streptozotocin-diabetic (B) and diabetic, Enalapril (C), Losartan (D), Spironolactone (E) and Eplerenone (F) treated rats (63x magnification; scale
bar–10 mm). Nuclei are stained blue with Hoechst. PT-proximal tubule, DT-distal tubule, Bm-basal membrane, Lu – apical membrane at the lumen and
Nucl – nuclei. Fluorescent signal intensity of NKA (green) generated from a line shown as red arrow in the merged image are shown on the bottom
right of each panel.
doi:10.1371/journal.pone.0039938.g003
Table 2. Mean arterial blood pressure (MAP) and heart rate of control, diabetic and treated diabetic rats.
Parameters Control Diabetic (D) D+Enalapril D+Losartan D+Spironolactone D+Eplerenone
MAP
(mmHg)
Before Treatment 105617 117620 103633 110618 118622 118625
After Treatment 100614 103621 116629 109617 108619 125611
Heart Rate
(bpm)
Before Treatment 443648 366647* 346641 334639 349632 366642
After Treatment 422670 350649* 356626 362643 4006201 3896351
Data are means 6 SD, n = 8–10/group, *p,0.05 vs. Control; 1p,0.05 vs. Diabetes, respectively. Bpm-beat/min.
doi:10.1371/journal.pone.0039938.t002
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reabsorb glucose is amplified as the filtered load is increased due to
the elevation in plasma glucose. In the present study aldosterone
blockade was the most effective in improving kidney function and
reducing renal structural damage. Since after aldosterone antag-
onist treatment blood glucose level was lower as well, one might
hypothesize that in these groups the reduced tubular glucose load
could lead to milder glucotoxicity-related kidney damage.
A Na+ gradient is required for the ongoing tubular transport of
glucose, which is created by the basolaterally located NKA [40]. In
diabetes NKA plays a role in the development of impaired renal
glucose and Na+ handling and in loss of renal function. However it
has already been demonstrated that NKA function is influenced by
ANGII inhibitors, in diabetes data are scarce with one study
reporting that ACEi prevents the increase of NKA in the diabetic
retina [41].
Previously in STZ-diabetic rats, we demonstrated that renal
NKA is elevated; the enzyme is mislocated from the tubular basal
membrane to the cytosol and becomes non-functional. This in line
with recent findings of Galuska et al showing that hyperglycemia
induces the mislocation of NKA from the basolateral membrane to
the cytosol in human tubular cell culture [42]. We also showed
that ANGII administration exerts similar changes, while ANGII
treatment in STZ-diabetes has a superimposed effect leading to
pronounced renal damage and NKA alteration [17]. Here we
extended our findings by showing that ACEi and ARB decreases
diabetes-induced NKA elevation and prevents enzyme misloca-
tion. Furthermore we demonstrated that aldosterone blockade is
even more effective in preventing these diabetic NKA alterations
than ACEi or ARB tretament. We confirmed these results also in
vitro, and showed that the changes in NKA are likely to be due to
the presence of hyperglycemia than to glucose-induced hyperos-
molarity.
According to our results a monotherapy with aldosterone
antagonists might be as, or more effective in the prevention of
STZ-induced DN, compared to ACEi or ARB. Moreover the
alteration of NKA could represent a novel pathophysiological
feature of DN and might serve as an additional target of RAAS
blockers. In summary our results might facilitate the monother-
apeutic application of Spironolactone and might open new
perspectives for Eplerenone in the clinical management of DN,
however well-controlled human clinical trials are needed to
confirm these suggestions.
Materials and Methods
Ethic Statement
All animal procedures were approved by the Committee on the
Care and Use of Laboratory Animals of the Council on Animal
Care at the Semmelweis University of Budapest, Hungary
(TUKEB 99/94).
Study design, Induction of Diabetes and Experimental
Groups
All substances were purchased from Sigma-Aldrich Ltd.
(Budapest, Hungary). Diabetes was induced in male Wistar rats
(175–200 g, 8 weeks) by 65 mg/kg STZ i.v. (dissolved in 0.1 M
citrate buffer; pH 4.5). Animals were considered diabetic if blood
glucose concentrations increased to $15 mmol/L within 72 h
after STZ injection and remained elevated. Five weeks after the
induction of diabetes, animals were randomly divided into five
groups and received by oral gavage (n = 8–10/group): vehicle (D);
ACEi Enalapril (D+Enalapril, 40 mg kg-1 day-1); ARB Losartan
(D+Losartan, 20 mg kg-1 day-1); the non-selective aldosterone
antagonist Spironolactone (D+Spironolactone, 50 mg kg-1 day-1)
or the selective aldosterone antagonist Eplerenone (D+Eplerenone
50 mg kg-1 day-1). As a result of the presence of a 9,11-epoxide
group in the structure of Eplerenone, its selectivity for the
aldosterone receptor is enhanced and its affinity for the
progesterone and androgen receptors is very low (i.e.,1 %
and,0.1 %, respectively, of the receptor binding of Spironolac-
tone). The doses were selected and adopted from previous studies
where effective blockade of ACE [25], ANGII receptor [26] and
aldosterone activity [27] was observed without leading to changes
of systemic blood pressure. Non-diabetic age-matched control
animals were injected with citrate buffer and sacrificed after
7 weeks (n = 8–10/group).
After 2 weeks of treatment with ACEi, ARB or aldosterone
antagonists rats were anesthesized, blood and urinary samples
were collected and the kidneys were removed, weighed and a
section fixed for histology and the remained immediately snap-
frozen for further investigations.
Measurement of arterial blood pressure
Arterial blood pressure (systolic, diastolic, mean (MAP)) and
heart rate were monitored from the tail artery with CODA
Standard monitor system (EMKA TECHNOLOGIES, Paris,
France), which uses proprietary volume pressure recording, a
clinically validated technology providing significant correlation
with telemetry [43].
Measurement of metabolic and renal parameters
Body and kidney weight were measured, kidney/body weight
ratio was calculated. Serum metabolic (glucose, total and HDL-
cholesterol, triglycerides) and renal functional parameters (sodium,
potassium, creatinine and BUN) were photometrically determined
with commercially available kits on a Hitachi 912 photometric
chemistry analyzer. Urinary protein to creatinine ratio was also
calculated.
Renal histology and morphometric analysis
Kidney was fixed in 10 % formalin, paraffin embedded, 5 mm
wide sections were taken and stained with periodic acid-Schiff
(PAS) for determination of glomerular matrix expansion, vascular
hyalinosis and tubulointerstitial lesions as previously described
[44]. Briefly, glomerular hypertrophy was determined by measur-
ing the glomerular tuft area of 50 glomerular cross-sections
excluding incomplete glomeruli along the sample edge. Hyaline
was determined by assessment of PAS-positive and nucleus-free
areas within the arterioles. Arteriolar hyalinosis was defined by the
average of hyalinized quarters of arterioles. The presence of
Armanni-Ebstein lesions was also evaluated. The analysis was
performed on a double blinded fashion with computer-assisted
morphometry using AxioVision 4.8 software on a Zeiss AxioIma-
ger A1 light-microscope.
Western blot analysis
All reagents for PAGE and Western blot were purchased from
Sigma-Aldrich Ltd. Kidney samples were sonicated and resus-
pended in lysis buffer. Protein concentration estimations were
performed with a detergent-compatible protein assay kit (Bio-Rad
Hungary, Budapest, Hungary). Samples containing 50 mg total
protein were electrophoretically resolved on a 10 % polyacryl-
amide gel and transferred to nitrocellulose membranes. The
membranes were incubated with the specific mouse NKA-a1
subunit (1:1,000, Santa Cruz Biotechnology, Budapest, Hungary)
antibody. After repeated washing the blots were incubated with
the corresponding goat anti-mouse (1:12,000, Santa Cruz
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Biotechnology) antibody. Non-diabetic rat brain cytosol was used
as a positive control.
Bands of interest were detected using enhanced chemilumines-
cence detection (ECL; GE Healthcare Life Sciences, Budapest,
Hungary) and quantified by densitometry (Versadoc, Quantity
One Analysis software; Bio-Rad Hungary) as integrated optical
density (IOD) after subtraction of background. The IOD was
factored for Ponceau red staining to correct for any variations in
total protein loading and for internal control (rat brain). The
protein abundance was represented as IOD/Ponceau S/Internal
control.
Fluorescent immunohistochemistry
Frozen kidney sections were embedded in Shandon cryomatrix
(Thermo Fisher Scientific) and cut to 5 mm slides with a cryostat.
Samples were incubated for one hour with the specific mouse
NKA-a1 (1:200, Santa Cruz Biotechnology) antibody. After
repeated washing slides were incubated with goat anti-mouse
Alexa Fluor 488 conjugate and counterstained with Hoechst
33342 (Sigma-Aldrich Ltd.) to visualize nuclei. Appropriate
controls were performed omitting the primary antibody to assure
the specificity and to avoid autofluorescence. Sections were
analyzed with a Zeiss LSM 510 Meta confocal laser scanning
microscope with objectives of 20x and 63x magnification.
Statistical analysis
Results were expressed as means6 SD. Statistical analyzes were
performed using Prism software (version 5.00; GraphPad Prism
Software, GraphPad Software, Inc., La Jolla, California, USA).
Multiple comparisons and possible interactions were evaluated by
one-way ANOVA followed by Fisher’s protected least significant
difference test. For non-parametrical data the Kruskal-Wallis
ANOVA on ranks was used. P values of,0.05 were considered
significant.
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